NCT02723994 2026-03-11A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic LeukemiaIncyte CorporationPhase 2 Completed171 enrolled
NCT02393859 2024-05-29Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)AmgenPhase 3 Completed111 enrolled 23 charts 1 FDA
NCT04943952 2021-08-03JZP458 - Recombinant Erwinia Asparaginase for Treatment of ALL / LBL Patients With Hypersensitivity to E. Coli-derived AsparaginaseJazz PharmaceuticalsApproved for marketing
NCT01643408 2021-06-23A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase TherapyJazz PharmaceuticalsPhase 2 Completed30 enrolled 11 charts
NCT00784017 2013-02-27Comparative Efficacy and Safety of Two Asparaginase Preparations in Children With Previously Untreated Acute Lymphoblastic Leukaemiamedac GmbHPhase 3 Completed199 enrolled
NCT00983138 2011-03-01Efficacy and Safety of Recombinant Asparaginase in Infants With Previously Untreated Acute Lymphoid Leukemia (ALL)medac GmbHPhase 2 Completed12 enrolled